TFPI inhibits lectin pathway of complement activation by direct interaction with MASP-2

European Journal of Immunology

Volumn 45, Issue 2, 2015, Pages 544-550

  Keizer, Mischa P ^a,b   Pouw, Richard B ^a   Kamp, Angela M ^a   Patiwael, Sanne ^a   Marsman, Gerben ^a   Hart, Margreet H ^a   Zeerleder, Sacha ^a   Kuijpers, Taco W ^a,b   Wouters, Diana ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Complement inhibition; Complement coagulation crosstalk; MASP 2; TFPI

Indexed keywords

LECTIN; MANNAN; MBL ASSOCIATED SERINE PROTEASE 2; MONOCLONAL ANTIBODY; SERINE PROTEINASE; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; CHROMOGENIC SUBSTRATE; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C4; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; MASP1 PROTEIN, HUMAN; MASP2 PROTEIN, HUMAN; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; SOLUTION AND SOLUBILITY;

ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; REPERFUSION INJURY; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPLEMENT LECTIN PATHWAY; GENETICS; IMMUNOASSAY; IMMUNOLOGY; PROTEIN TERTIARY STRUCTURE; SOLUTION AND SOLUBILITY;

ANTIBODIES, MONOCLONAL; CHROMOGENIC COMPOUNDS; COMPLEMENT C1R; COMPLEMENT C1S; COMPLEMENT C4; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; HUMANS; IMMUNOASSAY; LIPOPROTEINS; MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASES; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SERINE PROTEINASE INHIBITORS; SOLUTIONS;

EID: 84923031022     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201445070     Document Type: Article

References (24)

1. Hart, M. L., Ceonzo, K. A., Shaffer, L. A., Takahashi, K., Rother, R. P., Reenstra, W. R., Buras, J. A. et al., Gastrointestinal ischemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J. Immunol. 2005. 174: 6373-6380.
2. Osthoff, M., Katan, M., Fluri, F., Schuetz, P., Bingisser, R., Kappos, L., Steck, A. J. et al., Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients. PLoS One 2011. 6: e21338.
3. Schwaeble, W. J., Lynch, N. J., Clark, J. E., Marber, M., Samani, N. J., Ali, Y. M., Dudler, T. et al., Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc. Natl. Acad. Sci. U.S.A. 2011. 108: 7523-7528.
4. Parej, K., Dobo, J., Zavodszky, P. and Gal, P., The control of the complement lectin pathway activation revisited: both C1-inhibitor and antithrombin are likely physiological inhibitors, while alpha2-macroglobulin is not. Mol. Immunol. 2013. 54: 415-422.
5. Petersen, S. V., Thiel, S., Jensen, L., Vorup-Jensen, T., Koch, C. and Jensenius, J. C., Control of the classical and the MBL pathway of complement activation. Mol. Immunol. 2000. 37: 803-811.
6. Li, A. and Wun, T. C., Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity. Thromb. Haemost. 1998. 80: 423-427.
7. Bajaj, M. S., Birktoft, J. J., Steer, S. A. and Bajaj, S. P., Structure and biology of tissue factor pathway inhibitor. Thromb. Haemost. 2001. 86: 959-972.
8. Stephan, F., Dienava-Verdoold, I., Bulder, I., Wouters, D., Mast, A. E., Te, V. H., Aarden, L. A. et al., Tissue factor pathway inhibitor is an inhibitor of factor VII-activating protease. J. Thromb. Haemost. 2012. 10: 1165-1171.
9. Maroney, S. A., Hansen, K. G. and Mast, A. E., Cellular expression and biological activities of alternatively spliced forms of tissue factor pathway inhibitor. Curr. Opin. Hematol. 2013. 20: 403-409.
10. Tang, H., Ivanciu, L., Popescu, N., Peer, G., Hack, E., Lupu, C., Taylor, F. B., Jr. et al., Sepsis-induced coagulation in the baboon lung is associated with decreased tissue factor pathway inhibitor. Am. J. Pathol. 2007. 171: 1066-1077.
11. Frauenknecht, V., Thiel, S., Storm, L., Meier, N., Arnold, M., Schmid, J. P., Saner, H. et al., Plasma levels of mannan-binding lectin (MBL)-associated serine proteases (MASPs) and MBL-associated protein in cardio- and cerebrovascular diseases. Clin. Exp. Immunol. 2013. 173: 112-120.
12. Pavlov, V. I., Skjoedt, M. O., Siow, T. Y., Rosbjerg, A., Garred, P. and Stahl, G. L., Endogenous and natural complement inhibitor attenuates myocardial injury and arterial thrombogenesis. Circulation 2012. 126: 2227-2235.
13. Opal, S. M., Palardy, J. E., Parejo, N. A. and Creasey, A. A., The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit. Care Med. 2001. 29: 13-17.
14. Yoshimura, N., Kobayashi, Y., Nakamura, K., Yamagishi, H. and Oka, T., The effect of tissue factor pathway inhibitor on hepatic ischemic reperfusion injury of the rat. Transplantation 1999. 67: 45-53.
15. Abraham, E., Reinhart, K., Opal, S., Demeyer, I., Doig, C., Rodriguez, A. L., Beale, R. et al., Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003. 290: 238-247.
16. Abraham, E., Reinhart, K., Svoboda, P., Seibert, A., Olthoff, D., Dal, N. A., Postier, R. et al., Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit. Care Med. 2001. 29: 2081-2089.
17. Asgari, E., Farrar, C. A., Lynch, N., Ali, Y. M., Roscher, S., Stover, C., Zhou, W. et al., Mannan-binding lectin-associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4. FASEB J. 2014. 28: 3996-4003.
18. Bultink, I. E., Hamann, D., Seelen, M. A., Hart, M. H., Dijkmans, B. A., Daha, M. R. and Voskuyl, A. E., Deficiency of functional mannose-binding lectin is not associated with infections in patients with systemic lupus erythematosus. Arthritis Res. Ther. 2006. 8: R183.
19. Wolbink, G. J., Bollen, J., Baars, J. W., ten Berge, R. J., Swaak, A. J., Paardekooper, J. and Hack, C. E., Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J. Immunol. Methods 1993. 163: 67-76.
20. Vorup-Jensen, T., Sorensen, E. S., Jensen, U. B., Schwaeble, W., Kawasaki, T., Ma, Y., Uemura, K. et al., Recombinant expression of human mannan-binding lectin. Int. Immunopharmacol. 2001. 1: 677-687.
21. Thiel, S., Kolev, M., Degn, S., Steffensen, R., Hansen, A. G., Ruseva, M. and Jensenius, J. C., Polymorphisms in mannan-binding lectin (MBL)-associated serine protease 2 affect stability, binding to MBL, and enzymatic activity. J. Immunol. 2009. 182: 2939-2947.
22. Brouwer, N., Frakking, F. N., van de Wetering, M. D., van, H. M., Hart, M., Budde, I. K., Strengers, P. F. et al., Mannose-binding lectin (MBL) substitution: recovery of opsonic function in vivo lags behind MBL serum levels. J. Immunol. 2009. 183: 3496-3504.
23. Keizer, M. P., Kamp, A. M., Brouwer, N., van de Wetering, M. D., Wouters, D. and Kuijpers, T. W., Plasma-derived mannose-binding lectin shows a direct interaction with C1-inhibitor. Mol. Immunol. 2014. 58: 187-193.
24. Presanis, J. S., Hajela, K., Ambrus, G., Gal, P. and Sim, R. B., Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Mol. Immunol. 2004. 40: 921-929.